Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
|Articles|May 1, 1999
Supplements and Featured Publications
- Creating an Optimal Strategy for Treating Endometriosis and Chronic Pelvic Pain
- Volume 5
- Issue 5 Suppl
CME Quiz
Advertisement
Articles in this issue
over 27 years ago
Participating Facultyover 27 years ago
Introductionover 27 years ago
Evaluation of Lovelace Health Systems Chronic Pelvic Pain Protocolover 27 years ago
Clinical Diagnosis in the Evaluation of Chronic Pelvic Painover 27 years ago
Selected Abstractsover 27 years ago
BibliographyAdvertisement
Related to this article
Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.
Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
FDA approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatment options for those with disease progression.
A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Boarding admitted patients on inpatient floor hallways can alleviate emergency department (ED) crowding. Outcomes tend to be positive, but the published evidence is weak, according to this systematic review.
Advertisement
Advertisement
Trending on AJMC
1
Surrogate End Points, Drug Costs Complicate Oncology Formularies
2
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
3
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
4
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
5